---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-008076"
form_type: "8-K"
ticker: "ERNA"
cik: "0000748592"
company_name: "Ernexa Therapeutics Inc."
filed_at: "2023-02-22T23:59:59+00:00"
generated_at: "2026-06-19T05:43:16.209110+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Eterna enters exclusive license with Factor for patents; prior deal terminated

## Summary
- Exclusive worldwide license under Factor's patents for human uses; term ends Nov 22, 2027, auto-renewed 2.5 years if Eterna receives $100M in sublicense fees.
- Eterna pays Factor 20% of sublicense fees before expiration, 30% during renewal; CEO Matthew Angel is co-founder/CEO of Factor's parent (related party).
- Prior license agreement (April 2021, amended Nov 2022) terminated and superseded by this new agreement on Feb 20, 2023.

## SEC filing metadata
- accession: 0001140361-23-008076
- form_type: 8-K
- ticker: ERNA
- cik: 0000748592
- company_name: Ernexa Therapeutics Inc.
- filed_at: 2023-02-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/748592/000114036123008076/0001140361-23-008076-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/748592/000114036123008076/brhc10048628_form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-008076
- JSON: https://secwatch.observer/filing/0001140361-23-008076.json
- Plain text: https://secwatch.observer/filing/0001140361-23-008076.txt

## Key facts
- Material Agreements
  Ernexa Therapeutics Inc. entered into Exclusive License Agreement with Factor Bioscience Limited valued at 20% of Sublicense Fees before Expiration Date, 30% during Renewal Term; at least $100 million in sub (effective 2023-02-20).
  - Action: entry
  - Agreement: license
  - Counterparty: Factor Bioscience Limited
  - Value: 20% of Sublicense Fees before Expiration Date, 30% during Renewal Term; at least $100 million in sub
  - Effective: 2023-02-20
  source text: On February 20, 2023, Eterna Therapeutics Inc., a Delaware corporation (the “ Company ”), entered into an exclusive license agreement (the “ Exclusive License Agreement ”) with Factor Bioscience Limited (“ Factor ”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000114036123008076/0001140361-23-008076-index.htm
- Material Agreements
  Ernexa Therapeutics Inc. terminated Amended Factor License Agreement with Factor valued at Terminated and superseded by Exclusive License Agreement (effective 2023-02-20).
  - Action: termination
  - Agreement: license
  - Counterparty: Factor
  - Value: Terminated and superseded by Exclusive License Agreement
  - Effective: 2023-02-20
  source text: Effective on February 20, 2023, the Exclusive License Agreement terminated and superseded the Amended Factor License Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000114036123008076/0001140361-23-008076-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.